EP0262154A1 - Isolement de genes pour la biosynthese d'antibiotiques a base de polycetides - Google Patents

Isolement de genes pour la biosynthese d'antibiotiques a base de polycetides

Info

Publication number
EP0262154A1
EP0262154A1 EP19870900564 EP87900564A EP0262154A1 EP 0262154 A1 EP0262154 A1 EP 0262154A1 EP 19870900564 EP19870900564 EP 19870900564 EP 87900564 A EP87900564 A EP 87900564A EP 0262154 A1 EP0262154 A1 EP 0262154A1
Authority
EP
European Patent Office
Prior art keywords
fragment
gene
dna
nucleic acid
milbemycin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP19870900564
Other languages
German (de)
English (en)
Inventor
Gwynfor Owen Humphreys
Christopher Richard Bailey
Christine Ann Mckillop
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Mycogen Plant Science Inc
Original Assignee
Lubrizol Genetics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB858531036A external-priority patent/GB8531036D0/en
Priority claimed from GB868616851A external-priority patent/GB8616851D0/en
Application filed by Lubrizol Genetics Inc filed Critical Lubrizol Genetics Inc
Publication of EP0262154A1 publication Critical patent/EP0262154A1/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6888—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms
    • C12Q1/689—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms for bacteria
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/52—Genes encoding for enzymes or proenzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P17/00—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms
    • C12P17/02—Oxygen as only ring hetero atoms
    • C12P17/06—Oxygen as only ring hetero atoms containing a six-membered hetero ring, e.g. fluorescein

Definitions

  • the present invention relates to the identification and manipulation of genes coding for enzymes involved in the biosynthesis of polyketide antibiotics (as defined below), to the use of such identified or manipulated genes in the production of polyketide antibiotics and to microorganisms containing such manipulated genes.
  • Polyketides are a structurally and functionaly diverse group of natural products which are related by similarities in their biosynthesis rather than by particularf structural similarities.
  • Polyketide natural products have stgructures that are in a broad sense derived from a similar basic structure which consists of poly- ⁇ -ketomethylene chains (-[CHRO] -, where n can range from about 4 to 20).
  • Polyketides are distinguished from other natural products by the mechanism by which this basic structure is synthesized.
  • a schematic diagram for the polyketide pathway is presented in Figure 1.
  • the poly-3- ketomethylene chain is synthesized from a "starter" unit, an acyl-CoA ester, by stepwise condensations of malonyl-CoA units with concomitant decarboxyl ation steps.
  • the acyl-Coa ester "starter" unit varies depending on the particular polyketide.
  • the added alonyl units also vary with the polyketide and can be methyl malonyl, ethyl malonyl, and other alkyl malonyl groups.
  • polyketide synthase which accepts the precursor units, effects condensation and other ancillary reactions with intermediates remaining enzyme bound until the ultimate stabilized polyketide is formed and released. Only a yery few polyketide synthases have been characterized; however, polyketide synthases are believed to be similar in that they incorporate a site for binding of the acyl-CoA "starter" molecule, and have transacylase functions which effect condensations. Polyketide synthases, while related, are specific to the particular polyketide that is synthesized.
  • Polyketide synthases can display considerable differenceds in their specificity for different acyl-CoA "starter” molecules, specificity for different malonyl -CoA units, specificity for the particular order in which malonyl units are added to the chain, and for the presence of ancillary reactions occurring in association with the construction of the basic polyketide chain, including, among others, reductions, substitutions and cycl izations.
  • Polyketide antibiotics include the tetracyclines (e.g., oxytetracycline) , anthracyclines (e.g., daunorubicin), macrolides (e.g., erythromycin) , polyenes (e.g., amphotericin B) , polyethers (e.g., monensin), ansamycins (e.g., rifamycin), isochromanequi nones (e.g., actinorhodin), avermectins and milbemycins ("Economic Microbiology", Vol. 3, "Secondary Products of Metabolism", Ed.
  • tetracyclines e.g., oxytetracycline
  • anthracyclines e.g., daunorubicin
  • macrolides e.g., erythromycin
  • polyenes e.g., amphotericin B
  • polyethers e
  • the polyketide antibiotics represent a functionally diverse group including bacteriocides, fungicides, nematocides, insecticides and cytotoxic agents. It is believed that these antibiotics are synthesized via a polyketide pathway (vide supra, Figure 1).
  • biosynthetic genes for that antibiotic. Also included among biosynthetic genes are genes which do not encode enzymes which mediate a particular enzyme.
  • SHEET biosynthetic step but which are involved in some way in the regulation of expression of other biosynthetic genes. These regulatory genes are necessary in addition to those genes encoding biosynthetic enzymes to synthesize the antibiotic in vivo.
  • the order of steps is determined by ordering of mutants blocked at different steps within the pathway.
  • the order of the blocked mutants is established in cross complementation tests in which mutants with blocks later in the pathway supply mutants with earlier blocks with precursors in the biosynthesis and thus complement antibiotic produciton in the earlier blocked mutants.
  • Another method for isolating genes involved in antibiotic biosynthesis involves cloning from a microorganism which produces a polyketide antibiotic the gene which endows the microorganism with resistance to the polyketide antibiotic. Such a resistance gene must be present when the polyketide antibiotic would otherwise be lethal to the producing microorganism.
  • This approach is based on the knowledge that in several cases it has been shown that the antibiotic resistance gene maps closely (is linked) with the biosynthetic genes on the chromosome. Therefore, by cloning the region around the resistance gene, it is possible to clone the clustered antibiotic biosynthetic genes. This approach is exemplified in the cloning of the erythromycin biosynthetic cluster from S. erythreus by Stanzak _e_t _al_. (1985) Biotechnology 4_:229-232.
  • This method is applicable to the isolation of an individual biosynthetic gene or to the isolation of polyketide antibiotic biosynthetic gene clusters.
  • the method is particularly suited to the isolation of genes involved in the early steps of the biosynthesis of a polyketide antibiotic.
  • This method involves the introduction of DNA fragments containing the isolated genes or gene clusters into a suitable non-producing Streptomyces host strain wherein the introduced biosynthetic genes are expressed and the desired polyketide antibiotic is produced.
  • the present invention therefore provides, in a first aspect, a method for isolating a gene involved in the biosynthesis of a first polyketide antibiotic which comprises the steps of: a) preparing a clone library wherein each clone contains a fragment of DNA from a microorganism which produces said first polyketide antibiotic; b) screening said clone library for hybridization to a nucleic acid probe molecule which comprises the nucleic acid sequence of at least a part of a gene involved in the biosynthesis of a second polyketide antibiotic; and c) selecting those clones which hybridize to said nucleic acid probe molecule thereby isolating a clone which contains a fragment of DNA which comprises said gene involved in the biosynthesis of said first polyketide antibiotic.
  • the fragment of DNA contained in the clones which are found to hybridize to the antibiotic biosynthetic gene hybridization probe can in turn be used to further probe the clone library, or a second clone library. Fragments of DNA from hybridizing clones isolated in this manner, or combinations of such isolated fragments can then be tested for the ability to direct synthesis of the desired polyketide antibiotic in a strain of Streptomyces which does not normally produce the antibiotic. By following such a procedure it is possible to isolate and clone all the genes necessary in order to synthesize the polyketide antibiotic in a non-producing strain.
  • Fragments of isolated DNA which contain DNA from the microorganism that produces the first polyketide antibiotic can also be used for carrying out the method of the present invention with respect to other polyketide antibiotics. These fragments are particularly useful as probes for isolating the biosynthetic genes and gene clusters for polyketide antibiotics which are structurally similar to the first polyketide antibiotic.
  • the clone library or clone bank comprises preferably a library of bacteriophage, plasmid or, most preferably, cosmid clones.
  • the source of DNA for the clone library may comprise chromosomal, plasmid or prophage DNA from a microorganism that is a producer strain of the first polyketide antibiotic.
  • the microorganism from which the clone library is constructed is one that carries the biosynthetic genes for the production of the first polyketide antibiotic.
  • the microorganism can be a fungus or a bacterium, and is preferably an Actino ycete, most preferably a bacterium of the genus Streptomyces.
  • the hybridization probes used in this method comprise nucleic acid sequences and preferably comprise DNA.
  • SUBSTITUTE SHEET fragments may be identified. These large fragments may in some cases contain not only genes involved in the polyketide antibiotic synthesis, but genes and other DNA sequence not essential for antibiotic synthesis. It may be desirable, in such cases, to delete from such large cloned fragments, regions that are not essential for antibiotic synthesis.
  • biosynthetic gene clusters it may be the case that the genes required for synthesis of the polyketide antibiotic are found on two or more DNA fragments which span a contiguous region of the chromosome. In this case, it may be desirable to ligate the contiguous fragments together in order to construct a single DNA fragment which contains all of the required biosynthetic genes. It may also be desirable to delete non-essential regions from such a composite DNA fragment.
  • the isolation method of the present invention employs hybridization probes which comprise the nucleic acid sequence of at least part of a gene involved in an early step of the biosynthesis of the second polyketide antibiotic.
  • the isolation method of the present invention employs hybridization probes which comprise the nucleic acid sequence of at least a part of a gene involved in the biosynthesis of actinorhodin, particularly probes comprising the nucleic acid sequence of at least part of actinorhodin Gene I or actinorhodin Gene III.
  • the isolation method of the present invention employs hybridization probes which comprise the nucleic acid sequence of at least a part of a gene involved in the biosynthesis of milbemycin, particularly probes comprising the nucleic acid sequence of at least part of milbemycin Gene I or milbemycin Gene III.
  • the present invention also provides, in a second aspect, a method for producing a first polyketide antibiotic in a naturally non-producing strain of a bacterium of the genus Streptomyces which comprises the steps of:
  • each clone contains a fragment of DNA from a microorganism which produces said first polyketide antibiotic
  • nucleic acid probe molecule which comprises the nucleic acid sequence of at least a part of a gene involved in the biosynthesis of a second polyketide antibiotic
  • This method employs DNA fragments containing biosynthetic genes and gene clusters which are obtained by the isolation methods of the present invention.
  • DNA fragments containing the entire biosynthetic gene cluster for a polyketide antibiotic can be isolated and introduced into a non- producing strain in order to effect synthesis of the polyketide antibiotic.
  • Bacterial hosts which are suitable for use in this method are strains of bacteria of the genus Streptomyces which do not naturally produce the desired polyketide antibiotic. Suitable host strains are those that synthesize the necessary biochemical precursors for synthesis of the polyketide antibiotic, e.g. the appropriate acyl-CoA and malonyl-CoA precursors, and that are transformable. It is contemplated that strains of Streptomyces lividans, Streptomyces ambofaciens, Streptomyces coelicolor, Streptomyces avermitilis and Streptomyces parvulus will be particularly useful in this method. It may be that different Streptomyces host strains will be more or less preferably employed in this method dependent on the particular polyketide antibiotic to be synthesized.
  • One specific embodiment of the polyketide antibiotic production method of the present invention involves the production of milbemycins, particularly by introduction of the milbanycin biosynthetic gene cluster, or more particularly by introduction of DNA fragment MC or a DNA fragment that is functionally equivalent to fragment MC into a milbemycin non-producing strain of
  • Streptomyces It is contemplated in this embodiment that Streptomyces lividans is a suitable host strain.
  • Another specific embodiment of the present antibiotic production method involves production of avermectins in an appropriate host bacterium.
  • the present invention provides, in another aspect, a method for activating the expression of a polyketide antibiotic biosynthetic gene cluster
  • this method for activating expression of synthesis of a polyketide antibiotic can be applied to synthesis of actinorhodin, milbemycin and avermectin and particularly to the biosynthesis of one of these antibiotics in strains of Streptomyces lividans, Streptomyces coelicolor and Streptomyces avermitilis.
  • this method may also be employed to enhance the level of production of a polyketide antibiotic by introduction of milbemycin Gene II into a strain which naturally produces the polyketide antibiotic.
  • the present invention provides, in yet another aspect, DNA fragments and vectors containing these fragments which are useful in the methods of the present invention.
  • vectors are provided which comprise DNA fragments which consist essentially of the milbemycin biosynthetic gene cluster, preferably where the DNA fragment is fragment MC.
  • Vectors which comprise DNA molecules consisting essentially of the DNA sequence encoding a milbemycin biosynthetic gene are also provided, including those encoding milbemycin Gene I, milbemycin Gene II and milbemycin Gene III.
  • Vectors which comprise DNA molecules that are DNA fragment 1, fragment 2, fragment 3, fragment 4, fragment 5, fragment 6, fragment 7, fragment 8a, fragment 8b, fragment 10, fragment 12, fragment 14, fragment 16, fragment 62 and fragment 64 are also provided.
  • the vectors and DNA fragments provided herein are useful as hybridization probes or in some cases for introduction into appropriate host bacterial in order to effect synthesis of polyketide antibiotics or to effect a modification of a polyketide antibiotic naturally produced by the host strain.
  • hybridization probes provided in the present invention it is contemplated that in addition to the specific fragments identified, fragments that are functionally equivalent as hybridization probes to the specific DNA fragments identified are also part of the present invention. This includes hybridization probes that consist essential of the sequences of the fragments identified herein, as well as hybridization probes whose sequences are derived from the sequences of the fragments identified herein.
  • the present invention also provides a method for investigating the structure of a gene cluster for the synthesis of a first polyketide antibiotic comprising:
  • the expected result depends on the location of the gene fragment inserted in the phage. If the fragment is within a chromosomal transcription unit, it would be expected that in transformants, in which homologous recombi ation has caused the phage DNA to be integrated into the chromosomal DNA, disruption of transcription would occur, and no production of the antibiotic would be observed. Conversely, if the fragment includes a complete transcription unit, but no other parts of other transcription units, no disruption of transcription would be expected.
  • antibiotic production may be stopped whether or not the gene fragment comprises a complete transcription unit. Moreover, in some cases, whether antibiotic production is stopped is dependent on the orientation in the chromosomal DNA of the inserted phage DNA. This is not what would be expected from the work carried out by Chater and Bruton.
  • transformants having deletions in one direction may not affect antibiotic production, since the deletions will take place outside the gene cluster. However, transformants having deletions in the other direction may have antibiotic production disrupted by deletions occurring within the gene cluster.
  • the above investigation method can be used to determine whether a cloned gene fragment is actually within the desired gene cluster and to delimit the extent of the gene cluster.
  • the present invention in all its aspects also enables the skilled person readily: to investigate the biosynthesis of any particular polyketide antibiotic, which may lead to an improvement of the yield of the antibiotic; to investigate the effect of using genes from one microorganism on the biosynthesis of a polyketide antibiotic in another microorganism; or to produce novel polyketide antibiotics by insertion into a microorganism of combinations of genes or parts of genes isolated from different microorganisms.
  • novel polyketide antibiotics could be produced by causing mutations in isolated genes or by recombining parts of various genes, using conventional DNA techniques, and inserting the manipulated genes into a microorganism.
  • Figure 1 is a schematic diagram of the polyketide pathway.
  • Figure 2 shows the structural formul e of four representative polyketide antibiotics
  • Figure 3 provides restriction enzyme maps of the S. avermitilis DNA fragments inserted into plasmids pIJ 2303, pIJ 2305 and pIJ 2308; the location of certain actinorhodin genes within these inserts is also provided (Malpartida and Hopwood, 1986).
  • Figure 4 shows the results of Southern hybridization experiments using the pIJ 2305 fragment as a probe of Pstl digests of total chromosomal DNA of (1) S. coelicolor, (2) S. lividans and (3) Streptomyces sp. B41-146.
  • Figure 5 shows the restriction map of vector pIJ 610
  • Figure 6 shows the restriction map and relative arrangement of the fragments 8a, 8b and 10. The location of fragments 1, 2, 3, 4, 5, 6, 7, 14 and 16 is also provided.
  • Figure 7 shows the scheme for transferring the clone 8a insert into vector pIJ 922.
  • Figure 8 shows the restriction map and relative arrangement of the fragments 8a, 62 and 64.
  • Figure 9 shows a restriction map of the phage vector pP0D9.
  • Figure 10 shows the theoretical insertion of pPODll into the Streptomyces sp. B41-146 chromosome compared to the structure of one actual insertion event.
  • Figure 11 shows the theoretical insertion of pP0D12 into the Streptomyces sp. B41-146 chromosome compared to the structure of one actual insertion event.
  • Figure 12 shows the theoretical insertion of pP0D1071 into the Streptomyces sp. B41-146 chromosome compared to the structure of one actual insertion event.
  • Figure 13 shows the theoretical insertion of pP0D1072 into the
  • Streptomyces sp. B41-146 chromosome compared to the structure of one actual insertion event.
  • the present invention is based on the hypotheses that structurally similar condensation enzymes are involved in at least the early steps of the biosyntheses of polyketide antibiotics and that the several genes required for the biosynthesis of an individual polyketide antibiotics are clustered in the DNA of the microorganism that produces that polyketide antibiotic.
  • the group of polyketide natural products are defined by an overall similarity in the biosynthetic pathway by which they are synthesized in vivo and similar precursors may be involved in the synthesis of the basic polyketide chain. There is, however, much structural diversity among polyketides in general and specifically among the various polyketide antibiotics. The structurally diversity of the polyketide antibiotics reflects differences in their biosynthetic pathways. It is believed that major structural variation of the stabilized polyketide core are mediated not only by subsequent enzymatic modification of the basic polyketide chains but
  • condensation and other enzymes that function in the biosynthesis of other polyketide natural products are also functionally similar to those of polyketide antibiotic synthesis, suggesting that the early steps in the biosynthesis of many polyketides, including for example those of fatty acid biosynthesis may be mediated by functionally and therefore potentially structurally similar enzymes.
  • DNA hybridization is demonstrated between the actinorhodin biosynthetic genes, Gene I and Gene III, and Streptomyces sp. B41-146 DNA fragments that have been shown to contain genes involved in the biosynthesis of milbemycin.
  • the fact that it is possible to identify DNA fragments containing biosynthetic genes for one polyketide antibiotic by hybridization to probes containing biosynthetic genes for a structurally unrelated polyketide antibiotic is surprising and unexpected. It would be expected either that no hybridizing sequences would be identified or more likely that the hybridizing sequences so identified would not be specifically associated with the biosynthesis of the desired polyketide antibiotic.
  • Actinorhodin Gene I and Gene III are found to be blocked at the earliest steps in the biosynthetic pathway of actinorhodin (Malpartida and Hopwood, 1986). It is believed that these genes may be associated with the actinorhodin polyketide synthase.
  • actinorhodin genes the specific Streptomyces sp. B41-146 DNA that hybridizes to act Gene I is designated milbemycin Gene I and that which hybridizes to act Gene III is designated milbemycin Gene III.
  • milbemycin Gene I and milbemycin Gene III are associated with early steps in the biosynthesis of milbemycin, possibly associated with milbemycin polyketide synthase.
  • actinorhodin genes were in fact employed as probes in hybridization screens of a library of Streptomyces sp. B41-146 cloned DNA. Hybridization screens using an act Gene III probe resulted in the isolation of several DNA fragments (fragments 8a, 8b and 10, Figure 6). It was demonstrated by restriction enzyme mapping that these B41-146 DNA fragments overlap one another and span an approximately 48 kb long contiguous region. Act Gene III probe hybridization within this region was localized to a 1.6 kb BamHI restriction fragment, numbered fragment 4. The act Gene III probe also hybridized to fragments 1, 2 and 3 which al inc ude fragment 4 sequence.
  • Table 1 presents the results of complementation experiments, in which B41-146 fragments containing sequences that hybridized to act Gene I and act Gene III sequences were introduced into Streptomyces coelicolor mutants blocked in act Gene I (TK 17) or act Gene III (TK 18).
  • the B41-146 fragments contain DNA sequences which appear to functionally complement both act Gene I and Act Gene III and the complementary sequences correspond to those regions showing hybridization to the actinorhodin gene probes.
  • the interpretation of the results of Table 1 are complicated, however, by the leaky phenotype of the TK 17 mutant.
  • B41-146 fragment 7 was inserted in either orientation or when fragment 12 was inserted in one orientation that all transformed S. lividans produced actinorhodin.
  • the B41-146 DNA fragments therefore contain sequences that activate synthesis of the polyketide antibiotic actinorhodin. It has also be demonstrated that fragment 7 contains sequences, a gene, that functionally complements a Streptomyces coelicolor act Gene II mutation. The act Gene II is believed to be involved in the regulation of actinorhodin biosynthesis.
  • the B41-146 DNA sequence that functionally complement act Gene II are designated milbemycin Gene II and are by analogy expected to be involved in the regulation of milbemycin biosynthesis.
  • Fragment 7 does not show hybridization to act Gene II sequences, and is therefore not structurally similar to the actinorhodin regulatory gene. Act Gene II also activates actinorhodin production in transformed S. lividans. Horinouchi and Beppu (1984) Agric. Biol. Chem. 48_:2131-2133 have reported the isolation of a regulatory gene, afsB, which controls biosynthesis of A-f actor and which also controls the production of the red pigments, actinorhodin and prodigiosin. There is at present no indication that afsB is equivalent to either act Gene II or milbemycin Gene li ⁇
  • lt may be the case that many strains of Streptomyces contain silent biosynthetic genes for secondary metabolite production, including polyketide antibiotic production.
  • the milbemycin Gene II sequence and fragments containing it are useful in the activation of such silent polyketide antibiotic biosynthetic genes in strains like S. lividans and may be widely applicable in other Streptomyces species.
  • the milbemycin Gene II sequence may also be useful in the enhancement of the level of production of a polyketide antibiotic in a Streptomyces strain that naturally produces the antibiotic.
  • Fragments 10, 8b, 8a, 62 and 64 define and span a chromosomal region of about 62 kb in length. It is believed that this region contains the complete biosynthetic gene cluster for the production of milbemycin.
  • a composite fragment, fragment MC can be constructed by appropriate restriction enzyme cleavages, ligations and isolation of any intermediate DNA fragments and the desired MC fragment by conventional DNA isolation methods. Fragment MC spans 62 kb of DNA; however, by analogy with other polyketide antibiotics for which the complete biosynthetic gene cluster has been cloned, the milbemycin gene cluster should range in size between about 30 to 40 kb of DNA.
  • fragment MC contains in addition to the milbemycin biosynthetic gene cluster, other genes not involved in the biosynthesis. It is likely, based on the mapped locations of the milbemycin Gene I, II and III regions that DNA regions that are not essential for milbemycin production are located at the leftward end of fragment MC. Delineation of the region essential for milbemycin biosynthesis can be done by iterative removal of sequences at the left or right end of fragment MC coupled with intermediate testing of the resultant shorter DNA fragment for the ability to direct synthesis of milbemycin in a bacterial host which does not naturally produce
  • EET milbemycin e.g., S. lividans
  • Fragment MC and fragments derived therefrom that are essentially equivalent in function to fragment MC in that they contain the complete biosynthetic gene cluster for milbemycin production are useful in methods described herein for the production of milbemycin in non- mi Ibemycin producing strains of Streptomyces.
  • phage insertion will only cause the disruption of gene expression when the cloned DNA is internal to a transcription unit (i.e. contains neither the 5' nor the 3' end sequences of the transcription unit). It was found, however, using the DNA fragments and strains described herein that phage insertion most often induced disruption of gene expression. This was observed even with cloned DNA fragments, like fragment 4, which were believed to contain entire transcription units. It was found that this technique induced the deletion of both phage as well as chromosomal DNA. The technique therefore proved to be method for the production of milbemycin non- producing mutants. The results of these experiments coincidental ly provided another demonstration that the cloned B41-146 DNA of fragment MC contained genes associated with milbemycin production, since deletion of chromosomal DNA in this region resulted in non- producing mutants.
  • the techniques applied herein to the isolation of the milbemycin biosynthetic gene cluster define a general method for the isolation of polyketide antibiotic biosynthetic gene clusters. This method is an extension of the method described above for the isolation of polyketide antibiotic biosynthetic genes which comprises, after the initial selection of clones which hybridize to probes containing a gene or part of a gene involved in the biosynthesis of another polyketide antibiotic, iterative testing and rescreening steps by which chromosomal sequences adjacent to the initially selected DNA fragments are cloned.
  • the testing and rescreening steps are continued until the entire biosynthetic gene cluster is cloned, which is demonstrated by the detection of the production of the polyketide antibiotic in a naturally non- producing Streptomyces strain into which the cloned DNA region has been inserted. It may be desirable to ascertain by the use of appropriate controls that the introduced cloned DNA is directing synthesis of the polyketide antibiotic.
  • the polyketide antibiotic biosynthetic cluster can be employed for the production of the antibiotic in a suitable strain that does not naturally produce the antibiotic. It may be desired to produce an antibiotic in a heterologous host, because the chosen host provides some benefit for the production of the antibiotic, for example faster or more efficient growth or ease of isolation of the product antibiotic from growth medium.
  • B41-146 DNA that contain milbemycin Gene I and milbemycin Gene III, particularly fragments 4 and 5, are expected to be useful, as were the act Gene I and Act Gene III probes, as hybridization probes in the isolation of biosynthetic genes of a variety of polyketide antibiotics.
  • These fragments and also other B41-146 DNA fragments in the vicinity of the Gene I and Gene III sequences are expected to be particularly useful in the isolation of biosynthetic genes for polyketide antibiotics which are structurally similarly to milbemycin, for example, avermectins.
  • the hybridization methods described herein can be applied to the the isolation of biosynthetic genes for a variety of polyketide antibiotics.
  • the methods of the present invention enable the skilled person to identify and isolate the genes for polyketide antibiotic biosynthesis without having to follow the lengthy and tedious prior art process of mutant preparation, complementation and gene mapping.
  • this method can be applied in cases where mutant preparation is particularly onerous, as when the screening method for non-producing mutants involves chemical analysis rather that a more simple plate assay.
  • such a method can be applied in cases where there is no resistance gene associated with antibiotic biosynthesis, for example in those cases where the antibiotic is not toxic to bacteria (milbe ycins and avermectins).
  • SUBSTITUTE SHEET The methods of the invention involve the use of recombinant DNA techniques which are known per se and therefore do not form part of the invention. For instance, the preparation of clone libraries and the technique of hybridization screening are well known to a person skilled in the art. Thus, a skilled person will be able to carry out the methods of the present inventions using only his ordinary skill and knowledge of the art. A number of techniques that are standard in the art are described in: Maniatis et al. (1982) Molecular Cloning, Cold Spring Harbor Laboratory, Cold Spring Harbor, New York; Wu (ed.) (1979) Meth. Enzymol . 68_: Wu _et _a]_. (eds.) (1983) Meth.
  • pIJ2305 and pIJ2308 Two plasmids, which contain subfragments of the pIJ2303 insert, designated pIJ2305 and pIJ2308 were obtained from Bglll and Pstl digests, respectively, of pIJ2303.
  • Figure 3 also provides the restriction maps of the pIJ2305 and pIJ2308 inserts as well as the physical location of actinorhodin genes within these inserts.
  • filters were prehybridized for 2 hrs at 37°C in a solution containing 6x SSC (Salt-Sodium Citrate, where lxSSC is 0.15M NaCl , 0.15M trisodium citrate, pH 7.0)/ 50% v/v formamide; 0.1% wt/v SDS (Sodium dodecyl sulfate) and 50 ⁇ g/ml salmon sperm DNA.
  • 6x SSC Salt-Sodium Citrate, where lxSSC is 0.15M NaCl , 0.15M trisodium citrate, pH 7.0
  • 50% v/v formamide 0.1% wt/v SDS (Sodium dodecyl sulfate) and 50 ⁇ g/ml salmon sperm DNA.
  • Hybridization was performed at 37°C, overnight using the same solution. Filters were washed twice. First at 37°C for 1 hr. with a ⁇ xSSC/ 50% v/v formamide/0.1% wt/
  • a second actinorhodin gene probe specific for Gene I was prepared by digesting the pD2308 insert with BamHI and isolation of a 2.2 kb fragment which contains actinorhodin Gene I.
  • Example 2 Hybridization screening of a Streptomyces sp. B41-146 clone library with actinorhodin gene probes
  • a cosmid library of Streptomyces sp. B41-146 DNA was prepared by Sau3a digestion to give 20-30 kb fragments. The fragments were cloned into the Bglll site of the shuttle cosmid pIJ 610, which can be obtained from Tobias Kieser, John Innes Institute, using in vitro packaging techniques in Escherichia coli. A restriction map of vector pIJ 610 is shown in Figure 5. Selection for inserts is made on the basis of in vitro packaging size constraints in conjunction with phosphatased vector. The cosmid library thus prepared was screened by hybridization to the 1.1 kb BamHI fragment containing actinorhodin Gene III (vide supra). Conventional techniques were used.
  • filters were prehybridized at 37°C for 2.5 hr using a solution of 6xSSC/ 50% v/v formamide/ 0.1% SDS/ 50 ⁇ g/ml salmon sperm DNA. Hybridization was carried out overnight at 37°C using the same solution. Filters were washed at 37°C for 70 min. using 6xSSC/ 50% v/v formamide. Of 1,000 clones screened, 3 were found to hybridize to the actinorhodin Gene III probe. These clones were designated 8a, 8b, and 10. The fragments of Streptomyces sp. B41-146 DNA contained in these clones were also designated 8a, 8b and 10. Restriction maps of these fragments are shown in Figure 6.
  • fragments 8a, 8b and 10 are 32 kb, 29 kb and 29 kb respectively. Using conventional restriction enzyme analysis it was shown that these fragments overlap one another and span a contiguous region of Streptomyces sp. B41-146 DNA of about 48 kb. '
  • the fragments 8a, 8b and 10 and restriction subfrag ents thereof were also analyzed for hybridization to the 2.2 kb BamHI actinorhodin Gene I specific probe (vide supra). Again conventional Southern hybridization techniques were employed. Specifically, filters were prehybridized for 2 hr and hybridization was conducted at 37°C overnight as described above. Filters were washed at 37°C three times: first for 1 hr with 6x SSC/ 50% v/v formamide; then for 90 min with 2x SSC/ 50 % v/v formamide and then for 90 min with lx SSC/ 50% v/v formamide. The Gene I specific probe was found to hybridize to both fragments 8a and 8b, but not to fragment 10.
  • fragments 8a and 8b the probe was found to hybridize to a 4.2 kb BamHI subfragment, designated fragment 5; a 4.2 Pstl subfragment, designated fragment 6; and a 10 kb Bglll subfragment, designated fragment 7 (see figure 6).
  • fragment 8a includes sequences that hybridize to both actinorhodin gene specific probes.
  • Plasmid pIJ 922 (Lydiate _et__al_. (1985) Gene _35_: 223- 235) is a low copy number Streptomyces vector capable of carrying l rge inserts. This
  • SUBSTITUTE SHEET vector was chosen in preference to the shuttle cosmid, used in clone bank preparation, to avoid deletion of the inserted sequences when inserting clone 8a directly into Streptomyces.
  • Fragment 8a was digested with Bglll and a 13 kb Bglll subfragment which contained the actinorhodin Gene III hybridizing sequence and a 10 kb Bglll subfragment containing the actinorhodin Gene I hybridizing sequence were isolated. These subfragments were designated fragment 2 and fragment 7, respectively, as shown in figure 7. Digestion of the 8a fragment with BamHI allowed isolation of a 1.6 kb BamHI subfragment containing the Gene III hybridizing sequences, this subfragment was designated fragment 4 ( Figure 7). Fragments 2, 7 and 4 were cloned into vector p IJ943, which is another low copy number Streptomyces vector (available from David Hopwood, John Innes Institute). Insertion of DNA fragments into the Bgl II cloning site of pIJ 943 results in the loss of melanin production by the host bacterium, thus providing a convenient screen for insertion.
  • S. lividans contains the genes for production of actinorhodin, but does not normally produce this antibiotic.
  • a strain of this species, S. lividans TK24 (Keiser _et__al_. (1982) Mol. Gen. Genet. 185:223-228), was transformed with pIJ943 containing fragment 7 inserted in either orientation as well as with pIJ922 containing fragment 12 inserted in either orientation.
  • fragment 4 sequences functionally complement actinorhodin Gene II, no hybridization between fragment 7, milbemycin Gene II and actinorhodin Gene II sequences were detected. Sequences in fragment 7 are thus not structurally similar to those in Gene II.
  • Example 5 Extending the Streptomyces sp. B41-146 milbemycin gene cloned region to the right of fragment 8a
  • SUBSTITUTE SHEET obtained from Y. Nagamine. This vector was used because it showed no sequence homology to several commonly used E. coli plasmids, including pIMS6026 (Churchward, _et__a (1984) Gene .3 ⁇ :165-171).
  • Southern hybridization was carried out at 50°C with prehybridization for 3 hrs with 6xSSC/50% formamide/0.1% SDS/50 ⁇ g/ml herring sperm DNA, and hybridization overnight using the same solution. Four sequential 1 hr washes were used. The first with 6xSSC/50% formamide; the second with 2xSSC/50% formamide; the
  • Fragments 10, 8b, 8a, 62 and 64 define a Streptomyces sp. B41-146 region of about 62kb in length. It is believed that this DNA region contains the complete gene cluster for milbemycin production.
  • a composite fragment MC (approximately 62 kb) which contains the contiguous DNA of the milbemycin gene cluster is constructed from fragments 10, 8b, 8a, 62 and 64 by appropriate restriction enzyme cleavage and ligation steps with intermediate fragments and the 62 kb MC fragment isolated by conventional DNA gel separation techniques.
  • the phage vector used was phage pP0D9, the restriction map of which is shown if Figure 9.
  • This vector is derived by insertion of the tsr (thiostrepton resistance) gene (Thompson _et__al_. (1982) Gene _20_: 51-62) on a BclI-BamHI fragment into the BamHI site in the __ gene of the (DC31 derivcative (DC31 ⁇ W17, in which the attachment site is deleted (Chater _et__al_. (1981) Gene Jjj_: 249-256).
  • pP0D9 contains the tsr gene adjacent to a unique BamHI site.
  • Fragment 4 (1.6 kb BamHI fragment) which contains milbemycin Gene III was cloned into pP0D9 in both orientations to give phages pPODIO and pPODll ( Figure 10).
  • Fragment 16 (1.7 kb BamHI fragment) adjacent to Gene I was cloned to produce phage pP0D12 ( Figure 11).
  • Fragment 14 (1.9 kb BamHI fragment) was also cloned into pP0D9 in both orientations to give phages pP0D1071 and pP0D1072 ( Figures 12 and 13). These phages were used to infect wild-type Streptomyces sp. B41-146, and in each case individual thiostrepton resistant lysogens were assayed for milbemycin production.
  • FIG. 12 compares the expected insertion of pP0D1071 to the structure of lysogen pP0D1071/4(15). This lysogen, which suffered only a deletion of (D31 sequences, retains production of milbemycin.
  • Figure 13 compares the expected insertion of pP0D1072 with the structure of lysogen pP0D1072/2(10 which does not produce milbemycin. Again, a deletion of phage and chromosomal DNA was found in this lysogen.
  • the phage infection technique can therefore be used to creat a variety of milbemycin non- producing mutants by DNA deletions throughout the milbemycin biosynthetic cluster region. These mutants can be used in order to further investigate the genetics of milbemycin production and delineate other specific milbemycin genes within the milbemycin cluster region.
  • Example 7 Assays for milbemycin production
  • a plate assay for milbemycin production by bacteria was developed based on the nematocidal activity of milbemycin, and is herein exemplified for milbemycin production by Streptomyces sp. B41-146.
  • Streptomyces sp. B41-146 are plated on C agar medium (Goegelman et al . (1982) EPO Patent 058 513) at a density which allows formation of separate single colonies.
  • a suspension of nematodes (Caenorhabditis elegans) is added to the test plate containing bacterial colonies. Plates are initially examined for nematode density and viability and again after 3-10 hours for nematode kil ling.
  • C. elegans is cultured as described in Brenner (1974) Genetics 77:71- 94.
  • NG agar is seeded with the E. coli uracil alexotroph 0P50 in order to produce a bacterial lawn after incubation at 37°C for 18 hours.
  • a single hermaphrodite nematode (C. elegans strain N2) is added tot he bacterial lawn and the plate is incubated for 5 days at room temperature. After incubation the plate contains a dense population of C. elegans, which is then harvested using distilled water.
  • Seed medium 50 ml in a 250 ml baffled flask was inoculated with 50 ⁇ l of spores of the strain to be examined. The culture was incubated with shaking at 28°C for 12 days (Takiguchi t _ ⁇ ]_., 1983).
  • SUBSTITUTE SHEET extract were applied to a C18 reverse-phase HPLC column for analysis.
  • HPLC conditions used are those described in Takiguchi _et _al_. , 1983.
  • Column effluent was monitored at 240 n .
  • Act mutant 12 2 7 4 (27kb) (13 kb) (lOkb) (1.6 kb)
  • (+) complementation variable

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Analytical Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

Nouveaux procédés d'isolement et de caractérisation de gènes et de groupes de gènes utilisés dans la biosynthèse d'antibiotiques à base de polycétides. De nouveaux fragments d'ADN contenant ces gènes ainsi que des vecteurs contenant ces gènes et des souches bactériennes contenant ces vecteurs sont préparés par ces procédés. Les gènes et les groupes de gènes isolés par ces procédés sont également utilisés dans des procédés de production d'un antibiotique à base de polycétide dans des souches de streptomyces ne produisant pas naturellement l'antibiotique à base de polycétides.
EP19870900564 1985-12-17 1986-12-17 Isolement de genes pour la biosynthese d'antibiotiques a base de polycetides Withdrawn EP0262154A1 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB858531036A GB8531036D0 (en) 1985-12-17 1985-12-17 Genetic engineering method
GB8531036 1985-12-17
GB8616851 1986-07-10
GB868616851A GB8616851D0 (en) 1986-07-10 1986-07-10 Genetic engineering method

Related Child Applications (1)

Application Number Title Priority Date Filing Date
EP91202030A Division EP0463707A1 (fr) 1985-12-17 1986-12-17 Production d'antibiotiques à base de polycétides

Publications (1)

Publication Number Publication Date
EP0262154A1 true EP0262154A1 (fr) 1988-04-06

Family

ID=26290126

Family Applications (2)

Application Number Title Priority Date Filing Date
EP19870900564 Withdrawn EP0262154A1 (fr) 1985-12-17 1986-12-17 Isolement de genes pour la biosynthese d'antibiotiques a base de polycetides
EP91202030A Withdrawn EP0463707A1 (fr) 1985-12-17 1986-12-17 Production d'antibiotiques à base de polycétides

Family Applications After (1)

Application Number Title Priority Date Filing Date
EP91202030A Withdrawn EP0463707A1 (fr) 1985-12-17 1986-12-17 Production d'antibiotiques à base de polycétides

Country Status (4)

Country Link
EP (2) EP0262154A1 (fr)
JP (1) JPS63502636A (fr)
AU (1) AU598516B2 (fr)
WO (1) WO1987003907A1 (fr)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4935340A (en) * 1985-06-07 1990-06-19 Eli Lilly And Company Method of isolating antibiotic biosynthetic genes
GB8813055D0 (en) * 1988-06-02 1988-07-06 Beecham Group Plc Novel substance
EP0391594B1 (fr) * 1989-03-31 1995-10-18 Merck & Co. Inc. Clonage de gènes de Streptomyces avermitilis pour la biosynthèse de l'avermectine et procédés pour leur utilisation
US5252474A (en) * 1989-03-31 1993-10-12 Merck & Co., Inc. Cloning genes from Streptomyces avermitilis for avermectin biosynthesis and the methods for their use
AU676461B2 (en) * 1991-09-18 1997-03-13 Hoechst Aktiengesellschaft Secondary-metabolite biosynthesis genes from actinomycetes, method of isolating them, and their use
NZ245713A (en) * 1992-02-10 1994-12-22 Novopharm Ltd Production of the antibiotic lovastatin from genetically engineered aspergillus strains
JP3613614B2 (ja) * 1992-08-31 2005-01-26 シンジェンタ パーティシペーションズ アクチエンゲゼルシャフト 粘液細菌によるソラフェン生合成に関連するｄｎａ配列
FI942725A (fi) * 1993-12-16 1995-06-17 Pfizer Haaraketjuista alfaketohappodenydrogenaasikompleksia koodaavia geenejä Streptomyces avermitiliksesta
CA2239686A1 (fr) * 1995-12-07 1997-06-12 Recombinant Biocatalysis, Inc. Procede de detection d'une activite enzymatique
WO1997022711A1 (fr) 1995-12-19 1997-06-26 Regents Of The University Of Minnesota Procede metabolique de fabrication de synthases monomeres de polyhydroxyalcanoates
CA2197524A1 (fr) * 1996-02-22 1997-08-22 Bradley Stuart Dehoff Gene codant la polyketide synthase
CA2197160C (fr) * 1996-02-22 2007-05-01 Stanley Gene Burgett Gene codant la platenolide synthase
EP0929681B1 (fr) * 1996-08-20 2006-09-13 Novartis AG Groupe de genes de la biosynthese de la rifamycine
US6297007B1 (en) 1997-05-22 2001-10-02 Terragen Diversity Inc. Method for isolation of biosynthesis genes for bioactive molecules
US6143526A (en) * 1998-03-09 2000-11-07 Baltz; Richard H. Biosynthetic genes for spinosyn insecticide production
US6265202B1 (en) 1998-06-26 2001-07-24 Regents Of The University Of Minnesota DNA encoding methymycin and pikromycin
EP1477563A3 (fr) * 2003-05-16 2004-11-24 Wyeth Clonage de gènes de Streptomyces cyaneogriseus subsp.noncyanogenus pour la biosynthèse des antibiotiques et procédés pour leur utilisation

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3477936D1 (en) * 1983-03-08 1989-06-01 Merck & Co Inc Recombinant dna cloning vector pve1, deletion and hybrid mutants, and recombinant derivatives thereof, products and processes

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO8703907A1 *

Also Published As

Publication number Publication date
WO1987003907A1 (fr) 1987-07-02
EP0463707A1 (fr) 1992-01-02
AU6835487A (en) 1987-07-15
AU598516B2 (en) 1990-06-28
JPS63502636A (ja) 1988-10-06

Similar Documents

Publication Publication Date Title
AU598516B2 (en) Isolation of genes for biosynthesis of polyketide antibiotics
US5252474A (en) Cloning genes from Streptomyces avermitilis for avermectin biosynthesis and the methods for their use
Liu et al. Genes for production of the enediyne antitumor antibiotic C-1027 in Streptomyces globisporus are clustered with the cagA gene that encodes the C-1027 apoprotein
EP0346000A2 (fr) Gènes de biosynthèse de macrolides, pour utilisations dans des streptomyces et autres organismes
US7015001B2 (en) DNA encoding SPNF of the spinosyn cluster
Bate et al. The mycarose-biosynthetic genes of Streptomyces fradiae, producer of tylosin
Zotchev et al. Identification of a gene cluster for antibacterial polyketide-derived antibiotic biosynthesis in the nystatin producer Streptomyces noursei ATCC 11455
Bate et al. Differential roles of two SARP‐encoding regulatory genes during tylosin biosynthesis
Carmody et al. Analysis and manipulation of amphotericin biosynthetic genes by means of modified phage KC515 transduction techniques
Jensen et al. Five additional genes are involved in clavulanic acid biosynthesis in Streptomyces clavuligerus
JPH05317053A (ja) マクロライドの生合成のための遺伝子
US8652838B2 (en) Platensimycin biosynthetic gene cluster of Streptomyces platensis
WO2008021367A2 (fr) Compositions en relation avec la biosynthèse de la moenomycine, et procédés d'utilisation correspondants
AU652766B2 (en) Cloning of the biosynthetic pathway genes for chlortetracycline production from streptomyces aureofaciens and their expression in streptomyces lividans
US5876987A (en) Method, DNA and bacteria for hyperproduction of an antibiotic due to disruption of an AbsA gene
Mao et al. Genetic localization and molecular characterization of two key genes (mitAB) required for biosynthesis of the antitumor antibiotic mitomycin C
Arisawa et al. Direct fermentative production of acyltylosins by genetically-engineered strains of Streptomyces fradiae
US5589385A (en) Cloning of the biosynthetic pathway for chlortetracycline and tetracycline formation and cosmids useful therein
EP0391594B1 (fr) Clonage de gènes de Streptomyces avermitilis pour la biosynthèse de l'avermectine et procédés pour leur utilisation
Jones Cloning of streptomycete genes involved in antibiotic synthesis and its regulation
US5068189A (en) Recombinant dna vectors encoding a 4"-o-isovaleryl acylase derived from a carbomycin biosynthetic gene, designated care, for use in streptomyces and other organisms
CN103224905A (zh) 鉴定和表征来自生产多杀菌素的刺糖多孢菌的siponactin生物合成基因簇
US5024948A (en) Genetic system for micromonospora
Stratigopoulos et al. Inactivation of a transcriptional repressor during empirical improvement of the tylosin producer, Streptomyces fradiae
US6210935B1 (en) Staurosporin biosynthesis gene clusters

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19871231

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE FR GB IT LI LU NL SE

17Q First examination report despatched

Effective date: 19901126

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: LUBRIZOL GENETICS INC.

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 19930928

RIN1 Information on inventor provided before grant (corrected)

Inventor name: BAILEY, CHRISTOPHER, RICHARD

Inventor name: HUMPHREYS, GWYNFOR, OWEN

Inventor name: MCKILLOP, CHRISTINE, ANN